BioSpace News Archive

Sensorion is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, Italy.

LifeArc announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been acquired by ArcutisBiotherapeutics, Inc., a California-based early commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology.

Teva Pharmaceutical Industries Ltd. announces the results of two studies1,2 presented at the Migraine Trust International Symposium in London, UK, which demonstrate the efficacy of AJOVY▼ in migraine patients who also experience depression or anxiety.

Genus, a leading global animal genetics company, announces its preliminary results for the year ended 30 June 2022.

AlzeCure Pharma AB announced that the United States Patent Office has issued a patent covering ACD856, which is being developed against Alzheimer’s disease and other disorders with cognitive impairment.

An analysis from AbbVie’s three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.

Burning Rock Biotech Limited announced that all shareholder resolutions proposed at the Company’s 2022 annual general meeting held today were duly passed.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will participate in the Bank of America Global Healthcare Conference taking place September 15, 2022, in London, UK, at 1:20 pm British Summer Time.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the first patient implants in Canada with the Axonics F15™, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation system.

Cardinal Health announced Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company’s Pharmaceutical Segment.